Data Sheet (Cat.No.T15101)

TargetMol

Devazepide

Chemical Properties



CAS No. : 103420-77-5

Formula: C25H20N4O2

Molecular Weight: 408.45

Storage: Keep away from moisture,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Devazepide is a competitive, selective, orally available non-peptide CCK1 (cholecystokinin 1) receptor antagonist that inhibits bladder cancer cell proliferation and migration while inducing apoptosis and cell cycle arrest.
Targets(IC50)	Apoptosis,Cell Cycle Arrest,Cholecystokinin Receptor
In vivo	Oral gavage administration of Devazepide (4mg/kg, twice daily) significantly accelerated cholesterol crystal formation, crystal growth until developing into microlithiasis, and promoted gallstone formation in mice [2]. Intraperitoneal injection of Devazepide (0.1-1mg/kg) exerted opposing regulatory effects on the basal spontaneous activity of mice and the hypokinesia induced by caerulein and apomorphine [3].

Solubility Information

Solubility	DMSO: 160 mg/mL (391.72 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4483 mL	12.2414 mL	24.4828 mL
5 mM	0.4897 mL	2.4483 mL	4.8966 mL
10 mM	0.2448 mL	1.2241 mL	2.4483 mL
50 mM	0.049 mL	0.2448 mL	0.4897 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Chang RS, et al. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4923-6.
Helen H Wang, et al. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice. Eur J Clin Invest
E Vasar, et al. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology (Berl). 1991;105(3):393-9